CONTEXT: Interindividual variations in glucocorticoid sensitivity have been associated with manifestations of cortisol excess or deficiency and may be partly explained by polymorphisms in the human glucocorticoid receptor (hGR) gene. We studied a 43-yr-old female, who presented with manifestations consistent with tissue-selective glucocorticoid hypersensitivity. We detected a novel, single, heterozygous nucleotide (G --> C) substitution at position 1201 (exon 2) of the hGR gene, which resulted in aspartic acid to histidine substitution at amino acid position 401 in the amino-terminal domain of the hGRalpha. We investigated the molecular mechanisms of action of the natural mutant receptor hGRalphaD401H. METHODS- RESULTS: Compared with the wild-type hGRalpha, the mutant receptor hGRalphaD401H demonstrated a 2.4-fold increase in its ability to transactivate the glucocorticoid-inducible mouse mammary tumor virus promoter in response to dexamethasone but had similar affinity for the ligand (dissociation constant = 6.2 +/- 0.6 vs. 6.1 +/- 0.6 nm) and time to nuclear translocation (14.75 +/- 0.25 vs. 14.25 +/- 1.13 min). The mutant receptor hGRalphaD401H did not exert a dominant positive or negative effect upon the wild-type receptor, it preserved its ability to bind to glucocorticoid response elements, and displayed a normal interaction with the glucocorticoid receptor-interacting protein 1 coactivator. CONCLUSIONS: The mutant receptor hGRalphaD401H enhances the transcriptional activity of glucocorticoid-responsive genes. The presence of the D401H mutation may predispose subjects to obesity, hypertension, and other manifestations of the metabolic syndrome.
CONTEXT: Interindividual variations in glucocorticoid sensitivity have been associated with manifestations of cortisol excess or deficiency and may be partly explained by polymorphisms in the humanglucocorticoid receptor (hGR) gene. We studied a 43-yr-old female, who presented with manifestations consistent with tissue-selective glucocorticoid hypersensitivity. We detected a novel, single, heterozygous nucleotide (G --> C) substitution at position 1201 (exon 2) of the hGR gene, which resulted in aspartic acid to histidine substitution at amino acid position 401 in the amino-terminal domain of the hGRalpha. We investigated the molecular mechanisms of action of the natural mutant receptor hGRalphaD401H. METHODS- RESULTS: Compared with the wild-type hGRalpha, the mutant receptor hGRalphaD401H demonstrated a 2.4-fold increase in its ability to transactivate the glucocorticoid-inducible mouse mammary tumor virus promoter in response to dexamethasone but had similar affinity for the ligand (dissociation constant = 6.2 +/- 0.6 vs. 6.1 +/- 0.6 nm) and time to nuclear translocation (14.75 +/- 0.25 vs. 14.25 +/- 1.13 min). The mutant receptor hGRalphaD401H did not exert a dominant positive or negative effect upon the wild-type receptor, it preserved its ability to bind to glucocorticoid response elements, and displayed a normal interaction with the glucocorticoid receptor-interacting protein 1 coactivator. CONCLUSIONS: The mutant receptor hGRalphaD401H enhances the transcriptional activity of glucocorticoid-responsive genes. The presence of the D401H mutation may predispose subjects to obesity, hypertension, and other manifestations of the metabolic syndrome.
Authors: Elisabeth F C van Rossum; Richard A Feelders; Annewieke W van den Beld; André G Uitterlinden; Joop A M J L Janssen; Wietske Ester; Albert O Brinkmann; Diederick E Grobbee; Frank H de Jong; Huibert A P Pols; Jan W Koper; Steven W J Lamberts Journal: Am J Med Date: 2004-08-01 Impact factor: 4.965
Authors: Stefan Wüst; Elisabeth F C Van Rossum; Ilona S Federenko; Jan W Koper; Robert Kumsta; Dirk H Hellhammer Journal: J Clin Endocrinol Metab Date: 2004-02 Impact factor: 5.958
Authors: G I Perini; O Devinsky; P Hauser; W T Gallucci; W H Theodore; G P Chrousos; P W Gold; M A Kling Journal: J Clin Endocrinol Metab Date: 1992-02 Impact factor: 5.958
Authors: Richard J Santen; Christine M Jewell; Wei Yue; Daniel F Heitjan; Hershel Raff; Kevin S Katen; John A Cidlowski Journal: J Clin Endocrinol Metab Date: 2018-10-01 Impact factor: 5.958
Authors: Nicolas C Nicolaides; Zoi Galata; Tomoshige Kino; George P Chrousos; Evangelia Charmandari Journal: Steroids Date: 2009-10-07 Impact factor: 2.668
Authors: P Trebble; L Matthews; J Blaikley; A W O Wayte; G C M Black; A Wilton; D W Ray Journal: J Clin Endocrinol Metab Date: 2010-09-22 Impact factor: 5.958